Ron Leuty is a senior reporter for the Charlotte Business Journal, focusing on local biotech and healthcare news in the North Carolina area. With a background in biotech reporting, Ron covers a range of topics including drug approvals, medical research, and the business side of the biotech industry. His work has also been featured in Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
San Francisco, United States (Local)
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
Natalie Nakase's journey led her from UCLA walk-on to WNBA head coach with Golden State Valkyries
By: Ron Leuty
A Genentech breast cancer drug has won approval from the FDA more than a month ahead of schedule.
By: Ron Leuty
Preview this article The company last year won FDA approval of its drug for dialysis patients.
By: Ron Leuty
The small company, which until recently was working out of its founder's garage in Pleasanton, next year hopes to raise a Series A round of $8 million to $10 million.
Gritstone’s bankruptcy filing reveals biotech’s tough choices
By: Ron Leuty
Longtime biotech company builder lands CEO job
By: Ron Leuty
The drug at the center of a $21 billion acquisition by Gilead is being pulled from use for some patients.
Steph Curry is putting up a lot of shots off the basketball court
By: Ron Leuty
Inside baseball. Her first full season as a fan was Willie Mays' last as a player. Lisa Pantages' has run the bases from season ticket holder to CFO.
Gritstone Bio sets sale of assets through Bankruptcy Court
(833) 317-6278 
